AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
thiothixene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2639 | 3313-26-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 30 | mg | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 24, 1967 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AF04 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Thioxanthene derivatives |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| FDA EPC | N0000180182 | Typical Antipsychotic |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:149553 | anticoronaviral agent |
Related Drugs by ATC class:
N05AF Thioxanthene derivatives 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Senile dementia | contraindication | 15662003 | |
| Agranulocytosis | contraindication | 17182001 | DOID:12987 |
| Shock | contraindication | 27942005 | |
| Parkinsonism | contraindication | 32798002 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Stupor | contraindication | 89458003 | |
| Tardive dyskinesia | contraindication | 102449007 | |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Alcohol withdrawal syndrome | contraindication | 191480000 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Retention of urine | contraindication | 267064002 | |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Coma | contraindication | 371632003 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Drug Induced CNS Depression | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.72 | Basic |
| pKa2 | 4.65 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.35 | PDSP | CHEMBL | |||
| Alpha-2A adrenergic receptor | GPCR | Ki | 7.10 | PDSP | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.41 | PDSP | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 6.39 | PDSP | |||||
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 7.30 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.87 | PDSP | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.68 | PDSP | |||||
| 5-hydroxytryptamine receptor 7 | GPCR | Ki | 7.82 | PDSP | |||||
| Alpha-1A adrenergic receptor | GPCR | Ki | 7.94 | PDSP | |||||
| Alpha-2B adrenergic receptor | GPCR | Ki | 7.30 | PDSP | |||||
| D(3) dopamine receptor | GPCR | Ki | 9.41 | PDSP | |||||
| D(1B) dopamine receptor | GPCR | Ki | 6.58 | PDSP | |||||
| Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 8.40 | IUPHAR | ||||
| Histamine H2 receptor | GPCR | Ki | 6.39 | PDSP | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.59 | PDSP | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.68 | PDSP | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.40 | PDSP | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.81 | PDSP | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.32 | PDSP | |||||
| 5-hydroxytryptamine receptor 1B | GPCR | Ki | 6.82 | PDSP | |||||
| 5-hydroxytryptamine receptor 1D | GPCR | Ki | 6.18 | PDSP | |||||
| Alpha-2C adrenergic receptor | GPCR | Ki | 7.28 | PDSP | |||||
| D(4) dopamine receptor | GPCR | Ki | 6.69 | PDSP | |||||
| 5-hydroxytryptamine receptor 3A | Ion channel | Ki | 5.73 | PDSP | |||||
| Alpha-1B adrenergic receptor | GPCR | Ki | 7.46 | PDSP | |||||
| D(1A) dopamine receptor | GPCR | Ki | 7.29 | PDSP | |||||
| 5-hydroxytryptamine receptor 5A | GPCR | Ki | 6.44 | PDSP |
External reference:
| ID | Source |
|---|---|
| 4019947 | VUID |
| N0000148032 | NUI |
| D00374 | KEGG_DRUG |
| 4018509 | VANDF |
| 4019947 | VANDF |
| C0039955 | UMLSCUI |
| CHEBI:9571 | CHEBI |
| CHEMBL1201 | ChEMBL_ID |
| CHEMBL3989824 | ChEMBL_ID |
| D013888 | MESH_DESCRIPTOR_UI |
| DB01623 | DRUGBANK_ID |
| 212 | IUPHAR_LIGAND_ID |
| 2114 | INN_ID |
| 22189-31-7 | SECONDARY_CAS_RN |
| 7318FJ13YJ | UNII |
| 941651 | PUBCHEM_CID |
| 10510 | RXNORM |
| 2137 | MMSL |
| 5574 | MMSL |
| 5575 | MMSL |
| d00391 | MMSL |
| 001529 | NDDF |
| 001530 | NDDF |
| 25538002 | SNOMEDCT_US |
| 372804006 | SNOMEDCT_US |
| 62529008 | SNOMEDCT_US |
| 7318FJ13YJ | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-161 | CAPSULE | 5 mg | ORAL | ANDA | 18 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-275 | CAPSULE | 1 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-276 | CAPSULE | 2 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-277 | CAPSULE | 5 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-278 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0817 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-1129 | CAPSULE | 2 mg | ORAL | ANDA | 16 sections |
| thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1673 | CAPSULE | 1 mg | ORAL | ANDA | 17 sections |
| thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1674 | CAPSULE | 2 mg | ORAL | ANDA | 17 sections |
| thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1675 | CAPSULE | 5 mg | ORAL | ANDA | 17 sections |
| thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60219-1676 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67046-1542 | CAPSULE | 10 mg | ORAL | ANDA | 15 sections |
| Thiothixene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2486 | CAPSULE | 5 mg | ORAL | ANDA | 16 sections |
| Thiothixene | Human Prescription Drug Label | 1 | 70954-014 | CAPSULE | 1 mg | ORAL | ANDA | 16 sections |
| Thiothixene | Human Prescription Drug Label | 1 | 70954-015 | CAPSULE | 2 mg | ORAL | ANDA | 16 sections |
| Thiothixene | Human Prescription Drug Label | 1 | 70954-016 | CAPSULE | 5 mg | ORAL | ANDA | 16 sections |
| Thiothixene | Human Prescription Drug Label | 1 | 70954-017 | CAPSULE | 10 mg | ORAL | ANDA | 16 sections |